Phase 3 Readouts
Phase 3 clinical trial readouts are pivotal moments for biotech companies. These large-scale trials (1,000-5,000+ patients) determine whether a drug has enough evidence of efficacy and safety to seek FDA approval.
200 phase 3 readouts tracked, next on Jul 9, 2026. Updated .
Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. O
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effe
Dianthus Therapeutics, Inc. /DE/ (DNTH)
Phase 3 Topline: An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular
Milestone Pharmaceuticals Inc. (MIST)
Phase 3 Topline: A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP
Novartis AG (NVS)
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab
AMGEN INC (AMGN)
Phase 3 Topline: A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in P
Aardvark Therapeutics, Inc. (AARD)
Phase 3 Topline: Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastati
Sanofi (SNY)
Phase 3 Topline: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicron
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/
Novo Nordisk A/S (NVO)
Phase 3 Topline: Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability
NYMOX PHARMACEUTICAL CORP (NYMXF)
Phase 3 Topline: A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Che
AMGEN INC (AMGN)
Phase 3 Topline: An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24
AbbVie Inc. (ABBV)
Phase 3 Topline: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relations
ELI LILLY & Co (LLY)
Phase 3 Topline: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Wi
ELI LILLY & Co (LLY)
Phase 3 Topline: A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety o
ELI LILLY & Co (LLY)
Phase 3 Topline: Adjunctive Methylene BLUe in Septic SHock: a Pilot Randomized Controlled Trial
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED
BioNTech SE (BNTX)
Phase 3 Topline: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once W
ELI LILLY & Co (LLY)
Phase 3 Topline: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Wi
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Stu
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperp
Aardvark Therapeutics, Inc. (AARD)
Phase 3 Topline: A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1
Sanofi (SNY)
Phase 3 Topline: Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of C
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: An Open-label, Single-arm Study to Provide Efficacy and Safety Data of Voretigene Neparvovec Adminis
Novartis AG (NVS)
Phase 3 Topline: An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Eff
Apellis Pharmaceuticals, Inc. (APLS)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controll
ASTRAZENECA PLC (AZN)
Phase 3 Topline: An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and
BeOne Medicines Ltd. (ONC)
Phase 3 Topline: An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients Wi
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participat
KalVista Pharmaceuticals, Inc. (KALV)
Phase 3 Topline: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein
KalVista Pharmaceuticals, Inc. (KALV)
Phase 3 Topline: A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003
Viridian Therapeutics, Inc.\DE (VRDN)
Phase 3 Topline: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controll
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Phase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxici
Design Therapeutics, Inc. (DSGN)
Phase 3 Topline: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012
Incyte Corp. (INCY)
Phase 3 Topline: STEP: A Prospective, Interventional, Multicenter, Single-Arm Phase 3b Study to Evaluate the Step-Dow
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placeb
Merck & Co., Inc. (MRK)
Phase 3 Topline: A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Ch
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 3 Topline: Albumin in Acute Variceal Bleeding: A Randomized Controlled Trial: ALB-AVB Trial
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: Randomized, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole
X4 Pharmaceuticals, Inc (XFOR)
Phase 3 Topline: Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone F
Filana Therapeutics Inc. (FLNA)
Phase 3 Topline: A Randomized, Double-blind, Vehicle-controlled, Multicenter Phase III Study to Evaluate the Safety,
Biofrontera Inc. (BFRI)
Phase 3 Topline: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimil
Amphastar Pharmaceuticals, Inc. (AMPH)
Phase 3 Topline: A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate
Grifols S.A. (GRFS)
Phase 3 Topline: A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy
Arcus Biosciences, Inc. (RCUS)
Phase 3 Topline: An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refra
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthel
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To
NEUROCRINE BIOSCIENCES INC (NBIX)
Phase 3 Topline: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Predniso
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-3
Neumora Therapeutics, Inc. (NMRA)
Phase 3 Topline: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in
Vanda Pharmaceuticals Inc. (VNDA)
Phase 3 Topline: A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) an
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Phase 3 Topline: A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Effica
Novartis AG (NVS)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Ev
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Establ
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azaci
AbbVie Inc. (ABBV)
Phase 3 Topline: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Aveluma
Royalty Pharma plc (RPRX)
Phase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
ASTRAZENECA PLC (AZN)
Phase 3 Topline: An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety
FATE THERAPEUTICS INC (FATE)
Phase 3 Topline: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulves
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and
AMGEN INC (AMGN)
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel
AMGEN INC (AMGN)
Phase 3 Topline: An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or
KYNTRA BIO INC. (KYNB)
Phase 3 Topline: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein
Novartis AG (NVS)
Phase 3 Topline: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Mainten
Filana Therapeutics Inc. (FLNA)
Phase 3 Topline: A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Vers
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte S
TC BioPharm (Holdings) plc (TCBWF)
Phase 3 Topline: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
COMPASS Pathways plc (CMPS)
Phase 3 Topline: A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
PTC THERAPEUTICS, INC. (PTCT)
Phase 3 Topline: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN
PALVELLA THERAPEUTICS, INC. (PVLA)
Phase 3 Topline: Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Sa
Travere Therapeutics, Inc. (TVTX)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef
ELI LILLY & Co (LLY)
Phase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to So
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic R
Nasus Pharma Ltd (NSRX)
Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. O
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to De
Novartis AG (NVS)
Phase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT
BioNTech SE (BNTX)
Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndr
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica
TG THERAPEUTICS, INC. (TGTX)
Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re
Moderna, Inc. (MRNA)
Phase 3 Topline: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERA
BioNTech SE (BNTX)
Phase 3 Topline: A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162b2 (LP.8.1
BioNTech SE (BNTX)
Phase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Te
AbbVie Inc. (ABBV)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy
BIOMARIN PHARMACEUTICAL INC (BMRN)
Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Pa
Sol-Gel Technologies Ltd. (SLGL)
Phase 3 Topline: A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult P
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
Pharvaris N.V. (PHVS)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef
LEXICON PHARMACEUTICALS, INC. (LXRX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Serum Virus Neutralizing Antibody
Invivyd, Inc. (IVVD)
Phase 3 Topline: A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
Invivyd, Inc. (IVVD)
Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada
Akebia Therapeutics, Inc. (AKBA)
Phase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Sa
IONIS PHARMACEUTICALS INC (IONS)
Phase 3 Topline: Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multi
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Par
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezoliz
Jazz Pharmaceuticals plc (JAZZ)
Phase 3 Topline: A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa Pat
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
Zenas BioPharma, Inc. (ZBIO)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff
Sanofi (SNY)
Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Co
CYBIN INC. (HELP)
Phase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain
Alkermes plc. (ALKS)
Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double Bli
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
UroGen Pharma Ltd. (URGN)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff
Veradermics Incorporated (MANE)
Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi
ARDELYX, INC. (ARDX)
Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Afica
CYTOKINETICS INC (CYTK)
Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following
RenovoRx, Inc. (RNXT)
Phase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot
PFIZER INC (PFE)
Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone
Teva Pharmaceutical Industries Limited (TEVA)
Phase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Novartis AG (NVS)
Phase 3 Topline: A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investig
Sanofi (SNY)
Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI
Ocugen, Inc. (OCGN)
Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha
Novartis AG (NVS)
Phase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line
ASTRAZENECA PLC (AZN)
Phase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac
ARGENX SE (ARGX)
Phase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in Adu
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-
vTv Therapeutics Inc. (VTVT)
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a
Amylyx Pharmaceuticals, Inc. (AMLX)
Phase 3 Topline: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-double
GENELUX Corp (GNLX)
Phase 3 Topline: A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Organon & Co. (OGN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i
Xenon Pharmaceuticals Inc. (XENE)
Phase 3 Topline: A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Effi
Biohaven Ltd. (BHVN)
Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
Viridian Therapeutics, Inc.\DE (VRDN)
Phase 3 Topline: APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy,
Disc Medicine, Inc. (IRON)
Phase 3 Topline: US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol
Vistagen Therapeutics, Inc. (VTGN)
Phase 3 Topline: A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effica
SOLIGENIX, INC. (SNGX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compa
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates
Filana Therapeutics Inc. (FLNA)
Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan
Novo Nordisk A/S (NVO)
Phase 3 Topline: CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controll
Cardiol Therapeutics Inc. (CRDL)
Phase 3 Topline: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozel
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evalua
Novartis AG (NVS)
Phase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Topotecan Response and Toxicity
Design Therapeutics, Inc. (DSGN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
NYMOX PHARMACEUTICAL CORP (NYMXF)
Phase 3 Topline: A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Stu
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Randomized, Double-blind, Multicentre, Event-driven, Parallel Group, Phase III Study Evaluating th
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Dos
Sarepta Therapeutics, Inc. (SRPT)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLua
Dianthus Therapeutics, Inc. /DE/ (DNTH)
Phase 3 Topline: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Eff
Teva Pharmaceutical Industries Limited (TEVA)
Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva
Canopy Growth Corp (CGC)
Phase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to
AbbVie Inc. (ABBV)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a
Definium Therapeutics Inc. (DFTX)
Phase 3 Topline: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for
CG Oncology, Inc. (CGON)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific
Telix Pharmaceuticals Limited (TLX)
Phase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
SINOVAC BIOTECH LTD (SVA)
Phase 3 Topline: Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
MEDICURE INC (MCUJF)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet
Ensysce Biosciences Inc. (ENSC)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Met
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B,
Sanofi (SNY)
Phase 3 Topline: A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prosta
CG Oncology, Inc. (CGON)
Phase 3 Topline: REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil
Viridian Therapeutics, Inc.\DE (VRDN)
Phase 3 Topline: A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses
Novartis AG (NVS)
Phase 3 Topline: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Plat
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Design Therapeutics, Inc. (DSGN)
Phase 3 Topline: An Open-label Extension Study for Oral Rilzabrutinib in Adults With Chronic Immune Thrombocytopenia
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo Af
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Plac
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepa
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel
Compass Therapeutics, Inc. (CMPX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of
CAPRICOR THERAPEUTICS, INC. (CAPR)
Phase 3 Topline: A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate
Sanofi (SNY)
Phase 3 Topline: A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Ab
Krystal Biotech, Inc. (KRYS)
Phase 3 Topline: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing
Immunome Inc. (IMNM)
Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth
SELLAS Life Sciences Group, Inc. (SLS)
Phase 3 Topline: Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Eff
Viatris Inc (VTRS)
Phase 3 Topline: Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Wi
Praxis Precision Medicines, Inc. (PRAX)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placeb
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficac
Biohaven Ltd. (BHVN)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluatin
ELI LILLY & Co (LLY)
Phase 3 Topline: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, To
Xenon Pharmaceuticals Inc. (XENE)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compare
ELI LILLY & Co (LLY)
Frequently asked questions
What is a Phase 3 topline readout?
It is the first public release of primary-endpoint results from a pivotal Phase 3 trial, determining whether a drug has enough evidence to seek FDA approval.
Why are Phase 3 readouts high-risk catalysts?
Phase 3 trials are large and expensive; missing the primary endpoint can erase most of a clinical-stage company's value, while a hit de-risks the path to approval.
How are Phase 3 readout dates sourced?
Expected readout windows are derived from ClinicalTrials.gov completion dates and company guidance, updated hourly.
Learn more
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.